Results 51 to 60 of about 13,040 (222)

Assessment of the Performance of Siemens Scopio Digital Morphology on Bone Marrow Aspirates in Onco‐Hematology

International Journal of Laboratory Hematology, EarlyView.
ABSTRACT Objectives Digital morphology (DM) systems assisted by artificial intelligence are increasingly being introduced into hematology laboratories; however, data on their performance in routine clinical practice for bone marrow aspirates (BMA) remain limited.
Gina Zini, John Marra, Elena Rossi, Silvia Bellesi, Nicoletta Pelliccioni, Giuseppe d'Onofrio, Patrizia Chiusolo   +6 more
wiley   +1 more source

Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome

Haematologica, 2017
Paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome are diseases of excess activation of the alternative pathway of complement that are treated with eculizumab, a humanized monoclonal antibody against the terminal complement ...
Xuan Yuan, Eleni Gavriilaki, Jane A. Thanassi, Guangwei Yang, Andrea C. Baines, Steven D. Podos, Yongqing Huang, Mingjun Huang, Robert A. Brodsky   +8 more
doaj   +1 more source

Short‐Course Low‐Dose Primaquine for Radical Cure in G6PD‐Normal Patients in the Pre‐Elimination Context of Nepal

Tropical Medicine &International Health, EarlyView.
ABSTRACT Background Plasmodium vivax remains a challenge for malaria elimination in Nepal due to its ability to relapse. Radical cure with primaquine is effective but limited by poor adherence to the standard 14‐day low‐dose regimen. In 2022, the WHO recommended administering the same total dose (3.5 mg/kg) over 7 days to improve adherence.
Prakash Ghimire, Gokarna Dahal, Nabaraj Adhikari, Komal Raj Rijal, Sanjib Adhikari, Megha Raj Banjara, Hellen Mnjala, Grant Lee, Sophie Weston, Angela Rumaseb, Anjana Rai, Benedikt Ley, Mohammad Sharif Hossain, Julie A. Simpson, Megha Rajasekhar, Bipin Adhikari, Ric N. Price, Bibek K. Lal, Kamala Thriemer   +18 more
wiley   +1 more source

Comparison of four different in vitro assays for prediction of potential RBC antibody clinical significance

Transfusion, EarlyView.
Abstract Background The monocyte monolayer assay (MMA) uses monocytes, but it is known that antibody‐mediated hemolysis occurs in macrophages. Whether the use of macrophages would improve the predictive capacity of the MMA is unclear. Also, it is unclear if RBC alloantibodies contribute to hemolysis via antibody‐dependent cellular cytotoxicity (ADCC ...
Yeniley Ruiz Noa, Clémence Salou, Myriam Beshai, Selena Y. Cen, Lindsay K. Hillis, Katrina Billingsley, Donald R. Branch   +6 more
wiley   +1 more source

Outbreak of simultaneous poisoning by Froelichia humboldtiana (Roem. & Schult.) Seub and Indigofera suffruticosa in ruminants in the Sertão of Pernambuco, Brazil

Arquivo Brasileiro de Medicina Veterinária e Zootecnia
The occurrence of outbreak of poisoning due to a combination of plants is uncommon worldwide, and there are no records of similar cases in Brazil. An outbreak of poisoning by Froelichia humboldtiana and Indigofera suffruticosa in ruminants in the Sertão ...
C.A.O. Oliveira, J.K.A. Melo, D.C. Silva, K.C. Rocha, S.F. Lira, W.F. Souza, L.C.F. Baptista-Filho, T.R.R. Ramos   +7 more
doaj   +1 more source

Natural History of Chronic Kidney Disease in Sickle Cell Disease

American Journal of Hematology, Volume 101, Issue 7, Page 1456-1477, July 2026.
ABSTRACT Kidney complications, referred to as nephropathy, develop early in sickle cell disease (SCD). In addition to its known morbidity, abundant data show that chronic kidney disease (CKD) is associated with an increased mortality risk in SCD. Increasing evidence suggests that the natural history of SCD nephropathy is progressive. Initial glomerular
Kenneth I. Ataga
wiley   +1 more source

Frequency of Paroxysmal Nocturnal Hemoglobinuria Clone in Turkish Myelodysplastic Syndrome Group [PDF]

, 2018
Aim:Retrospective, cross-sectional, observational study to examine the frequency and features of paroxysmal nocturnal hemoglobinuria (PNH) clones in patients with myelodysplastic syndrome (MDS).Methods:Data were analyzed from the medical files of 41 MDS ...
Mesut Ayer, Tayfun Elibol, Merve Öztürk Çiloğlu, Fuat Şar, Esra Hayriye Ataoğlu, Fatma Aylin Ayer, Onur Hakkı Kırkızlar   +6 more
core   +1 more source

Paroxysmal Nocturnal Hemoglobinuria [PDF]

Blood, 1950
Abstract 1. Paroxysmal noctural hemoglobinuria is believed to be an acquired disease of the hematopoietic system in which abnormal red cells, white cells, and platelets are produced. The lesion of the cells probably involves the stromal proteins in such a fashion that they are susceptible to the proteolytic effect of a sytem of normal ...
openaire   +2 more sources

Safety and Effectiveness of Sutimlimab in Cold Agglutinin Disease: A Real‐World International Experience

American Journal of Hematology, Volume 101, Issue 7, Page 1597-1604, July 2026.
ABSTRACT Sutimlimab is a monoclonal antibody against complement fraction C1s approved for the treatment of hemolytic anemia due to cold agglutinin disease (CAD). Here, we analyzed and report the largest international CAD cohort of sutimlimab‐treated patients ever reported to highlight its safety and effectiveness in the real‐world setting. We accrued a
Bruno Fattizzo, Elisa Sambruna, Yoshitaka Miyakawa, Marc Michel, Carlo Visco, Michael Fillitz, George Kannourakis, Maria Bruna Greve, Moritz Kleemiss, Johan Cid, Andrea Patriarca, Laura Pavan, Arbana Dizdari, Nilla Maschio, Antonella Sau, Cinzia Bitetti, Riccardo Mario Colombo, Luigi Curreli, Dorela Lame, Uros Markovic, Fabrizio Pappagallo, Giacinto Luca Pedone, Davide Rapezzi, Vincenzo Sammartano, Nicola Tumedei, Antonio Giovanni Solimando, Jalink Marit, Luana Fianchi, Jahanzaib Khwaja, Antonio De Vivo, Francesco Lanza, Fabrizio Vianello, Esther N. Oliva, Catherine Broome, Francesco Passamonti, Ulrich Jaeger, Bernd Jilma, Guillaume Moulis, Wilma Barcellini   +38 more
wiley   +1 more source

Carbon Footprint of Antibody‐Based Drugs and Biologics Using Hybrid Life Cycle Assessment

Clinical Pharmacology &Therapeutics, Volume 120, Issue 1, Page 236-244, July 2026.
Life cycle assessment of monoclonal antibodies. Biological engineering has emerged since the 1980s as one of the most efficient technologies to develop new medicines. The monoclonal antibody platform is the most widely used, representing about 15–20% of drug sales.
Sébastien Taillemite, Martin Fenelon, Marc Scherlinger, Max Piffoux   +3 more
wiley   +1 more source